1016234-87-9

Basic information

• Product Name: 4-Bromo-5-fluoro-2-nitrophenol
• Synonyms: 4-Bromo-5-fluoro-2-nitrophenol;4-Bromo-5-fluoro-2-nitrophenol 97%;5-Bromo-4-fluoro-2-hydroxynitrobenzene
• CAS NO: 1016234-87-9
• Molecular Formula: C₆H₃BrFNO₃
• Molecular Weight: 235.9953232
• Mol File: 1016234-87-9.mol

Chemical Properties

• Boiling Point: 266.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.965±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 5.35±0.27(Predicted)
• CAS DataBase Reference: 4-Bromo-5-fluoro-2-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-5-fluoro-2-nitrophenol(1016234-87-9)
• EPA Substance Registry System: 4-Bromo-5-fluoro-2-nitrophenol(1016234-87-9)

Safety Data

• Hazardous Substances Data: 1016234-87-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-5-fluoro-2-nitrophenol is used as a key intermediate in the synthesis of various pharmaceuticals, particularly for the development of anticancer drugs and antiseptics. Its reactivity and structural features allow it to be a building block in the creation of these medicinal compounds, contributing to their therapeutic properties.
Used in Dye Industry:
In the dye industry, 4-Bromo-5-fluoro-2-nitrophenol is utilized as an intermediate in the production of dyes. Its chemical structure provides a foundation for the development of colorants used in various applications, such as textiles, plastics, and printing inks.
Used in Specialty Chemicals:
4-Bromo-5-fluoro-2-nitrophenol also serves as a versatile building block in the synthesis of specialty chemicals. Its unique combination of bromine, fluorine, and nitro groups allows it to be a component in the production of compounds with specific properties required for niche applications.
It is crucial to handle and store 4-Bromo-5-fluoro-2-nitrophenol with care due to its potential hazards if mismanaged, emphasizing the need for proper safety measures in its use and disposal.

Upstream product

• 446-36-6 5-fluoro-2-nitrophenol 
• 121219-03-2 4-bromo-3-fluorophenol 

Downstream Products

• 1016234-89-1 2-amino-4-bromo-5-fluorophenol 
• 1016235-10-1 (-)-(cis)-7-bromo-8,12-difluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-amine (4S)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1 : 1) 
• 1016234-91-5 4-bromo-2-[[(2,4-difluorophenyl)methylene]amino]-5-fluorophenol 
• 1352244-78-0 1-(2-bromo-5-methoxy-4-nitrophenyl)-4-methylpiperazine 

Relevant articles and documents

Crystal structure and catalytic properties of a vanadium complex cis-[VO2(Him-py)(im-py)]2·3H2O

The coordination behavior of Him-py (2-(1H-imidazol-2-yl)pyridine) toward vanadium has been explored. The six-coordinate complex, cis-[VO2(Him-py)(im-py)]2·3H2O (1), was synthesized by the coordination reaction of NH4VO3 and Him-py in the aqueous methanol solution, which was characterized by single-crystal X-ray technology. It belongs to the monoclinic space group P21/n with a = 8.0756(6), b = 19.3531(15), c = 11.4433(8), β = 106.905(2), V = 1711.2(2), and Z = 2. The crystal structure shows that the six-coordinate vanadium is bonded to two cis-oxido ligands and two bidentate ligands, Him-py and im-py. Interestingly, when crystals of 1 were immersed in H2O2, a peroxovanadium compound, (H2im-py)[OV(O2)2(Him-py)] (2), was obtained, which crystallizes in the orthorhombic space group Fdd2 with a = 22.600(2), b = 22.7259(13), c = 18.0146(11), V = 9252.4(12), and Z = 16, and consists of a seven-coordinate peroxovanadate(V) ion, one Him-py and one H2im-py ligand. Moreover, we also studied the catalytic activity of 1 in the oxidative bromination of phenol/aniline-like compounds towards mimicking bromoperoxidase reactivity.

Crystal structure, NMR and catalytic properties of a bis-peroxovanadium [NH4][VO(O2)2(mpa)]·H2O

By reacting NH4VO3 and mpa (mpa = 4-methoxypicolinamide) in the presence of H2O2, a bis-peroxovanadium [NH4][VO(O2)2(mpa)]·H2O (1) was obtained and characterized by X-ray single-crystal diffraction. Structural analyses demonstrate that 1 belongs to the monoclinic space group P21/c and consists of a bis-peroxovanadium [VO(O2)2(mpa)]?, one NH4+ counterion and one free lattice water. Adjacent [VO(O2)2(mpa)]? anions construct a 3D supramolecular framework through intra- and intermolecular hydrogen bonding interactions. The compositions of 1 in solution are investigated by using multinuclear (1H, 13C, and 51V) magnetic resonance, COSY, HSQC, HMBC, and variable temperature NMR in a 0.15 mol L?1 NaCl/D2O solution that mimics the physiological conditions. Comparing the results of single-crystal X-ray and NMR experiments, the VV ion in the undissociated [VO(O2)2(mpa)]? in solution displays a similar seven-coordinate distorted pentagonal bipyramidal geometry with the solid-state crystal. The catalytic activity of the 1 in the oxidative bromination for phenol/aniline-like compounds to mimic bromoperoxidases reactivity was also studied.

NOVEL PROTEIN KINASE INHIBITORS

The present disclosure describes novel protein kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such protein kinase inhibitors and methods of using them for treating cancer and other diseases, conditions, or disorders, which respond to the inhibition of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) activity, or a combination thereof, are also described.

Novel pyrimidine derivative showing growth inhibition of cancer cell and pharmaceutical composition comprising the same

The present invention provides a novel compound represented by chemical formula 1 or a salt thereof, and a pharmaceutical composition for treating lung cancer containing the same. Since the pyrimidine derivative compound represented by the chemical formul

ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.

TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE

The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS

The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical comp

New progesterone receptor modulators

The present invention provides new progesterone receptor modulators which are (cis)-8-fluorodibenzo[b,f]pyrido[1,2-d]oxazepine-1-amine compounds and uses thereof.

PYRIDOOXAZEPINE PROGESTERON RECEPTOR MODULATORS

The present invention provides new progesterone receptor modulators (I) and (II) which are (cis)-8-fluorodibenzo[b,f]pyrido[1,2-d] oxazepine-1 -amine compounds and uses thereof.